

RESEARCH ARTICLE

Open Access

Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China

Chun-fang Ma¹, Fang-qiu Li^{1,2*}, Li-ning Shi¹, Yu-an Hu¹, Ying Wang¹, Mei Huang¹ and Qian-qian Kong¹

Abstract

Background: Bloodstream infections due to *Candida* species cause significant morbidity and mortality, and the epidemiology of *Candida* infection is changing. Surveillance for candidemia is necessary to detect trends in species distribution and antifungal resistance.

Methods: The medical and electronic records of all patients who had candidemia at the authors' hospital from 2009 to 2011 were reviewed for demographic data and clinical information, including the infecting *Candida* species, resistance to antifungals and survival, and the presence of risk factors associated with candidemia.

Results: A total of 133 distinct episodes of candidemia were identified over the study period. The annual incidence of candidemia ranged between 0.71 and 0.85 cases/1000 hospital discharges. The most frequent *Candida* species were *C. tropicalis* (28.6%), followed by *C. albicans* (23.3%) and *C. parapsilosis* (19.5%). The rates of susceptibility to antifungal agents were as followed: voriconazole (97.8%), itraconazole (69.5%), fluconazole (46.1%), ketoconazole (38.9%). Out of 131 evaluable patients, 34 (26.0%) died within 30 days from the onset of candidemia. *C. tropicalis* candidemia was associated with the highest mortality rate (44.7%). Regarding the crude mortality in the different units, patients in Hemato-Oncology ward had the highest mortality rate (66.7%), followed by patients in cardiovascular wards and ICU (57.1% and 25.6%, respectively). Predictors of 30-day mortality were identified by uni- and multivariate analyses. Complicated abdominal surgery, presence of central venous catheter (CVC), neutropenia, candidemia due to *C. tropicalis* and poor treatment with fluconazole were significantly associated with the 30-day mortality. Presence of CVC (odds ratio[OR] = 4.177; 95% confidence interval [CI] = 1.698 to 10.278; $P = 0.002$) was the only independent predictor for mortality in the multivariate analysis.

Conclusion: This report provides baseline data for future epidemiological and susceptibility studies and for the mortality rates associated with candidemia in our hospital. The knowledge of the local epidemiological trends in *Candida* species isolated in blood cultures is important to guide therapeutic choices.

Keywords: Nosocomial candidemia, Antifungal susceptibility, Mortality, Risk factors

* Correspondence: njlifq@163.com

¹Laboratory of Molecular Biology, Institute of Medical Laboratory Sciences, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, P.R. China

²Laboratory of Molecular Biology, Institute of Medical Laboratory Sciences, Jinling Hospital, 305 East Zhongshan Road, Nanjing 210002, P. R. China

Background

Candida spp. is one of the most frequent pathogens isolated in bloodstream infections (BSI), and is associated with significant morbidity and mortality [1,2]. During the past two decades, the incidence of candidemia has been doubled and *Candida* spp. currently ranks as the fourth and the seventh most common bloodstream pathogen in North American and European studies [3,4]. The reasons for the increasing candidemia rates include improved detection as well as increase in patient-population at risk, such as invasive procedures and devices, broad-spectrum antimicrobial agents, advanced life-support and aggressive chemotherapy are more extensively used [5].

Candidemia have been associated with high crude and attributable mortality rates, especially among critically ill patients. The crude mortality rate of these infections is 40%-75% and the attributable mortality of candidemia has been estimated at 25%-38% [6,7]. In addition, an increase of 30 days in the length of hospital stay among patients surviving these infections has been demonstrated [8]. The economic impact of these infections is also important: candidemia has been associated with increased costs of care and prolonged hospitalization [9].

Historically, *Candida albicans* is the most common cause of candidemia worldwide. However, in recent years, some studies have reported an increase of candidemia due to non-*albicans Candida* species, with the threat of increased mortality and antifungal drug resistance [10,11]. The intrinsic and emerging resistance to azoles actually represents a major challenge for empirical therapeutic and prophylactic strategies [12].

The epidemiology of candidemia shows a wide variation among different countries. For example, an increasing incidence of candidemia in Iceland was reported for the period between 2000 and 2011 [13], but the similarity was not observed in Switzerland, where a national surveillance study showed that the incidence of candidemia had remained unchanged during the period of 1991 to 2000 [4]. Despite the epidemiology of candidemia has been studied extensively in the United States, Europe, and some countries in South America, very few studies have addressed these issues in China, where the differences about the demographic characteristics, health care practices, patterns using blood cultures, and antibiotic usage as well as the resistance situation do exist compared to other countries. In the present study, a three-year retrospective analysis was conducted to evaluate the incidence, species distribution, the associated resistance patterns of *Candida* species for the contemporary azole antifungal agents, outcome of candidemia BSI and risk factors for mortality in patients with candidemia in Jinling hospital, Nanjing, China.

Methods

Collection of patients

In our previous study, we developed two enzyme-linked immunosorbent assays to detect specific antibodies against *Candida* Eno and Fba1, and investigated the diagnostic value for invasive *Candida* infections by analyzing sera from patients with candidemia [14]. The purpose of current study was to investigate the state of *Candida* invasive infection. We conducted a retrospective observational study of computerized laboratory records of positive blood cultures at Jinling Hospital (Nanjing, China), a 1,800 beds tertiary care hospital with about 55,000 admissions per year from January 2009 to December 2011. The target population consisted of hospitalized patients presenting risk factors for candidemia, especially patients receiving broad-spectrum antibiotics, immunosuppressive therapy, parenteral nutrition, abdominal/thoracic surgery and hematopoietic transplantation, or those patients who had a long intensive care unit stay or acute renal failure. An episode of candidemia was defined as the isolation of a *Candida* species from blood culture in a patient with temporally related clinical signs and symptoms, such as fever, chills, or hypotension. For each patient, only the first episode of candidemia was included. Patients whose cultures grew >1 species of *Candida* were excluded from the analysis and all data were collected by using the electronic medical records. The following data were retrospectively collected: basic demographics, underlying disease, the specific fungal pathogen and species, resistance to antifungals and survival. The presence of risk factors associated with candidemia were also collected: systemic corticosteroid treatment (a dose equivalent to prednisone 10 mg/d for at least 14 days), neutropenia (absolute neutrophil count <500 cells/ μ l), complicated abdominal surgery (severe acute pancreatitis, and complex ventral hernia), acute renal failure (sudden and often temporary loss of kidney function with nitrogen waste retention and hypouricemia), indwelling central vascular catheter, intensive care unit hospitalization or mechanical ventilation. Early mortality was defined as death within seven days and late mortality as death between seven and 30 days [15]. The study protocol was approved by the Medical Ethics Committee of Jinling hospital.

Organism identification

A volume of 3 ml blood for children and 5 ~ 10 ml blood for adults was collected aseptically by skin venipuncture taken from different parts of each patient. The blood was inoculated into both BacT/AlerT 3D aerobic and anaerobic vials (Becton Dickinson). All positive cultures were manually sampled and inoculated on CHROMagar *Candida* medium (CHROMagar Company, Paris France) to ensure viability and purity. An aliquot was Gram-stained for preliminary identification of the microorganism. Identifi-

fication of all species was confirmed with the Vitek-2 system (bioMérieux, France).

Agar diffusion method

The growth inhibition zone and the category (resistant, intermediate and susceptible) were determined for fluconazole (FLC), itraconazole (ITC), ketoconazole (KTC), voriconazole (VOR), using a commercial agar diffusion test with Neo-Sensitabs® tablets (Rosco, Denmark). Neo-Sensitabs® sensitivity testing is a standardized agar diffusion method which includes antifungal agents in tablets of 9 mm of diameter with FLC (25 µg), ITC (8 µg), KTC (15 µg) and VOR (1 µg). Neo-Sensitabs® assay was performed according to the manufacturer's instructions [16]. Inocula contained 5×10^5 cells/ml and were prepared from an overnight subculture on Sabouraud glucose agar (Difco, USA), getting suspensions corresponding to McFarland 0.5 standard and then diluted (1:1) with sterile saline solutions. For *C. krusei* isolates inocula were equivalent to McFarland 0.5 standard, diluted 1:10 in saline solutions. Two milliliters of each inoculum suspensions were poured onto the agar surface and later removing the liquid in excess. Opened plates were dried at 35°C for 15 min before tablets will be placed on the agar surface.

Shadomy modified medium was used (Yeast Nitrogen Base, asparagine and glucose) with phosphate buffer to pH 7 and containing chloramphenicol to avoid bacterial contamination. Media was heated at 100°C during 15 min, and then cooled to 60°C before pouring the medium in Petri dishes (12 cm × 12 cm). A pre-diffusion drying was made at 37°C during 15 min. After an incubation period of 20-24 h, the inhibition diameter zones were read in mm with a caliper (Mitutoyo, Japan). Zone diameters were measured to the nearest whole millimeter at a point in which there was a prominent reduction of growth (80% for azoles). Depending on the diameter of the inhibition zone, *Candida* strains were classified as susceptible (S), intermediate (I) or resistant (R) to tested antifungals. The basic criterion according to manufacturers instructions was as follows: FLC ($S \geq 19$ mm, $I 18 \sim 15$ mm, $R \leq 14$ mm); ITC ($S \geq 15$ mm, $I 14 \sim 10$ mm, $R < 10$ mm); KTC ($S \geq 28$ mm, $I 27 \sim 21$ mm, $R \leq 20$ mm); VOR ($S \geq 17$ mm, $I 16 \sim 14$ mm, $R \leq 13$ mm).

Statistical analyses

In the assessment of predictors of poor outcome, we compared patients who survived until day 30 after the incident candidemia with those who died. Univariate analysis was performed using Fisher exact test or Chi-squared test for categorical variables. All variables with P -value < 0.1 by univariate analysis were entered in a logistic regression model. Kaplan-Meier curves were constructed to assess survival, and curve comparisons were performed by the Log Rank test. All tests were

two-tailed and a level of significance of $P < 0.05$ was considered statistically significant. Statistical analysis was performed using SPSS 18.0 for Windows (SPSS, Chicago, IL, USA).

Results

A total of 133 distinct episodes of candidemia (130 adults and 3 children < 15 years of age) were identified during the study period. Most candidemia was reported in adults (97.7%). More candidemia occurred among males (68.4%) than females, mainly in those over 60 years of age (Table 1). The mean annual incidence of candidaemia was 0.77 per 1000 admission. The incidence of candidemia increased from 0.71 in 2009 to 0.85 episodes/1000 admission in 2011. But the change in incidence over time did not reach statistical significance. The demographic and clinical characteristics of the patients are summarized in Table 1. Most patients had one or more comorbidity at the time of the diagnosis of candidaemia. The most common underlying conditions documented prior to candidemia were intestinal fistula/abdominal infection (55.7%), respiratory dysfunction (12.8%), and gastrointestinal pathology (10.2%).

The percentages of the three most common *Candida* spp. isolated were as follows: *C. tropicalis* (28.6%), *C. albicans* (23.3%) and *C. parapsilosis* (19.5%) (Table 1). The causative organism varied according to age of patients and their underlying diseases. With increasing age, a reduction in the percentage of *C. albicans* (from 33.3% to 23%) and *C. tropicalis* (from 33.3% to 27.9%) and a significant increase of *C. parapsilosis* (from 0 to 21.3%) was observed. Non-*albicans Candida* species were isolated with the highest frequency from patients with respiratory dysfunction (82.4%) and haematological malignancies (83.3%), in which *C. tropicalis* was the predominant species (64.7% and 83.3%, respectively).

The distribution of isolated *Candida* species is shown in Figure 1. Globally, the high rates of candidemia infection are not limited to ICU but also occurred on general wards. Out of 133 evaluable patients, 51 (38.3%) were hospitalized in ward of general surgery, this proportion being a small amount higher than that which arose from patients in ICU (23.3%). The distribution of *Candida albicans* and non-*albicans Candida* species differed according to the type of patient population and risk factors, as shown in Figure 1. In patients with hematologic malignancies, *C. albicans* accounted for 16.7% of the cases and *C. tropicalis* for 83.3%; In ICU *C. albicans* was isolated in 17.9% of the cases, *C. tropicalis* in 30.8% and *C. parapsilosis* in 20.5%; on the other hand in oncology *C. albicans* was isolated in 50% of the cases.

Table 2 summarizes the results of in vitro susceptibility testing of bloodstream isolates of *Candida* in the study. Consistent with previous reports [17,18], voriconazole

Table 1 Patient characteristics and incidence (episode/1000 admission)

	Candida species							
	Total	C. tropicalis	C. albicans	C. parapsilosis	C. glabrata	C. krusei	C. guilliermondii	Other*
	(n = 133)	(n = 38)	(n = 31)	(n = 26)	(n = 11)	(n = 3)	(n = 6)	(n = 18)
	100.0%	28.6%	23.3%	19.5%	8.3%	2.3%	4.5%	13.5%
Patients characteristic								
Age (years)								
1-14	3(2.3)	1(33.3)	1(33.3)	0(0)	0(0)	0(0)	0(0)	1(33.3)
15-49	29(21.8)	7(24.1)	9(31.0)	5(17.2)	3(10.3)	0(0)	1(3.4)	4(13.8)
50-65	40(30.1)	13(32.5)	7(17.5)	8(20.0)	3(7.5)	1(2.5)	4(10.0)	4(10.0)
>65	61(45.9)	17(27.9)	14(23.0)	13(21.3)	5(8.2)	2(3.3)	1(1.6)	9(14.8)
Gender								
Male	91(68.4)	28(30.8)	20(22.0)	18(19.8)	6(6.6)	2(2.2)	2(2.2)	15(16.5)
Female	42(31.6)	10(23.8)	11(26.2)	8(19.0)	5(11.9)	1(2.4)	4(9.5)	3(7.1)
Underline diseases n (%)								
Intestinal fistula/abdominal infection	74(55.7)	14(18.9)	20(27.0)	15(20.3)	6(8.1)	3(4.1)	5(6.8)	11(14.9)
Solid tumor	8(6.0)	2(25.0)	2(25.0)	1(12.5)	2(25.0)	0(0)	0(0)	1(12.5)
Respiratory dysfunction ^a	17(12.8)	11(64.7)	3(17.6)	1(5.9)	0(0)	0(0)	0(0)	2(11.8)
Gastrointestinal pathology ^b	14(10.5)	4(28.6)	1(7.1)	5(35.7)	1(7.1)	0(0)	1(7.1)	2(14.3)
Haematological malignancy	6(4.5)	5(83.3)	1(16.7)	0(0)	0(0)	0(0)	0(0)	0(0)
Acute renal failure ^c	11(8.3)	1(9.1)	3(27.3)	4(36.4)	2(18.2)	0(0)	0(0)	1(9.1)
Burns	3(2.3)	1(33.3)	1(33.3)	0(0)	0(0)	0(0)	0(0)	1(33.3)
Receipt of corticosteroids	76(57.1)	21(27.6)	17(22.4)	15(19.7)	5(6.6)	1(1.3)	2(2.6)	15(19.7)
Chemotherapy	6(4.5)	5(83.3)	1(16.7)	0(0)	0(0)	0(0)	0(0)	0(0)
Presence of CVC ^d	61(45.9)	19(31.1)	13(21.3)	11(18.0)	5(8.2)	2(3.3)	4(6.6)	7(11.5)
Parenteral nutrition	61(45.9)	20(32.8)	18(29.5)	6(9.8)	8(13.1)	1(1.6)	3(4.9)	5(8.2)
Mechanical ventilation	17(12.8)	6(35.3)	5(29.4)	2(11.8)	2(11.8)	0(0)	0(0)	2(11.8)
In the ICU at diagnosis	39(29.3)	14(35.9)	9(23.1)	8(20.5)	3(7.7)	2(5.1)	0(0)	3(7.7)
Neutropenia ^e	6(4.5)	2(33.3)	2(33.3)	0(0)	2(33.3)	0(0)	0(0)	0(0)
Dialysis	2(1.5)	0(0)	1(50.0)	1(50.0)	0(0)	0(0)	0(0)	0(0)
Exposition to antibiotics	80(60.2)	29(36.3)	23(28.8)	20(25.0)	3(3.8)	2(2.6)	1(1.3)	2(2.6)
Treatment with fluconazole	61(45.9)	23(37.7)	18(29.5)	5(8.2)	3(4.9)	3(4.9)	2(3.3)	7(11.5)
Incidence (episodes/1000 admissions)								
2009	0.71	0.19	0.22	0.11	0.06	0.02	0.04	0.06
2010	0.77	0.18	0.15	0.23	0.02	0.03	0.03	0.15
2011	0.85	0.31	0.19	0.13	0.13	0	0.03	0.12

*Others include: *C. pelliculosa*(8), *C. famata*(7) and *C. haemulonii*(2).

^aIncludes the following diseases: pneumonia, chronic obstructive pulmonary disease, and acute respiratory distress syndrome.

^bIncludes the following diseases: cholecystitis, pancreatitis, peritonitis, and hepatitis.

^cAcute renal failure was defined as sudden and often temporary loss of kidney function with nitrogen waste retention and hypouricemia.

^dCVC central venous catheter.

^eNeutropenia was defined as absolute neutrophil count <500 cells/μl.

demonstrated excellent in vitro potency against *Candida* species, nearly all strains (97.8%) were susceptible to VOR. With regard to KTC, the rate of resistant is particularly high in *Candida* spp. (61.9%), almost all isolates were resistant to KTC. ITC resistance was observed for 30.5% of all *Candida* isolates evaluated and was also highest among *C. glabrata* isolates (90.9% resistance). Most strains (53.9%)

became resistant to FLC, only 8 *C. albicans* BSI isolates (25.8%) collected during the 3-year surveillance program were reported as resistant. Decreased susceptibility to FLC was mostly seen with *C. glabrata* (90.9% resistance) and *C. tropicalis* (68.4% resistance). The percentages of yeast isolates with resistance and decreased susceptibility to FLC were similar during the three phases.



Figure 1 Distribution of the *Candida* species according to underlying pathology/medical care (n).

Outcome at day 30 was available for 131 episodes; patients in the remaining 2 episodes were lost to follow up. The crude mortality rate was 26.0%; Seven patients died within 48 hours of obtaining the blood culture, the time by which positive blood culture reports became available. This overall mortality rate varied according to the patients with different species of *Candida*, as well as the underlying disease or condition, the highest mortality rate was observed for *C. tropicalis* fungemia (44.7%). Haematological malignancy (66.7%), cardiovascular disease (57.1%), and intensive care in adults (25.6%) were associated more frequently with death during the study period.

Univariate predictors of poor outcome in candidemia is shown in Table 3. For candidemic patients, the variables associated with 30-day mortality were as follows: complicated abdominal surgery, presence of CVC, neu-

tropenia, candidemia due to *C. tropicalis*. Major factor associated with 30-day survival was receipt of fluconazole as primary treatment for candidemia. Because neutropenia was associated with poor outcome and this variable was available in only 6 of the 131 patients, this variable was not included in the multiply logistic regression model. As shown in Table 4, predictors of 30-day mortality by multivariate analysis among patients with candidemia were presence of CVC (OR 4.177; 95% CI 1.698-10.278; $P = 0.002$).

Discussion

In recent years, some studies have reported that the incidence of candidemia is increasing in many hospitals around the world. Our data show that in our hospital the incidence of candidemia has increased steadily in the

Table 2 Antifungal susceptibility of *Candida* bloodstream isolates in patients during the study period

Species	Fluconazole		Itraconazole		Ketoconazole		Voriconazole	
	No. of isolates tested	%S [#]	No. of isolates tested	%S	No. of isolates tested	%S	No. of isolates tested	%S
<i>C. albicans</i>	31	23 (74.2)	31	29 (93.6)	6	3 (50.0)	22	22 (100.0)
<i>C. parapsilosis</i>	26	15 (57.7)	26	25 (96.2)	2	1 (50.0)	22	22 (100.0)
<i>C. glabrata</i>	11	1 (9.1)	11	1 (9.1)	1	0 (0)	5	5 (100.0)
<i>C. tropicalis</i>	38	12 (31.6)	38	25 (65.8)	5	0 (0)	23	21 (91.3)
<i>C. krusei</i>	3	0 (0)	3	1 (33.3)	1	0 (0)	3	3 (100.0)
<i>C. guilliermondii</i>	6	4 (66.7)	6	5 (83.3)	0	0 (0)	5	5 (100.0)
Other [*]	16	4 (25.0)	16	5 (31.3)	3	3 (100.0)	12	12 (100.0)
Total	128	59 (46.1)	131	91 (69.5) [*]	18	7 (38.9)	92	90 (97.8)

^{*}; Others include: *C. pelliculosa*, *C. famata* and *C. haemulonii*.

[#]; Abbreviations: S susceptible.

Table 3 Factors associated with 30-day mortality by univariate analysis in candidemic patients

Variable	30-day outcome		P-value
	Survived N = 97	Died N = 34	
Median age, years (range)	61 (0-88)	69 (0-73)	0.58
Gender (male:female)	68:29	23:11	0.889
In the ICU at diagnosis, n (%)	30 (30.9)	9 (26.5)	0.457
Mechanical ventilation, n (%)	10 (10.3)	7 (20.6)	0.109
Parenteral nutrition, n (%)	43 (44.3)	18 (52.9)	0.952
Complicated abdominal surgery, n (%)	21 (21.6)	14 (41.2)	0.019
Presence of CVC, n (%)	34 (35.1)	27 (79.4)	<0.001
Receipt of corticosteroids, n (%)	53 (54.6)	23 (67.6)	0.397
Neutropenia, n (%)	2 (2.1)	4 (11.8)	0.015
Species, n (%)			
<i>C. albicans</i>	25 (25.8)	6 (17.6)	0.508
<i>C. tropicalis</i>	21 (21.6)	17 (50.0)	0.002
<i>C. parapsilosis</i>	19 (19.6)	5 (14.7)	0.444
<i>C. glabrata</i>	8 (8.2)	3 (8.8)	0.928
<i>C. krusei</i>	2 (2.1)	1 (2.9)	0.575
Treatment with antibiotics, n (%)	57 (58.8)	23 (67.6)	0.600
Treatment with fluconazole, n (%)	51 (52.6)	10 (29.4)	0.019

ICU intensive care unit, CVC central venous catheter.

past three years in parallel with medical technological advances. The incidence is somewhat higher than that reported for centers in Denmark (0.41 case per 1000 admissions) [19], Israel (0.50 case per 1000 admissions) [20], China (0.53 cases per 1000 admissions) [21], and much lower than that reported in Brazil (1.87 cases per 1000 admissions) [22]. The differences in candidemia rates between countries may reflect differences in demographic characteristics, variations in health care practice, patterns using blood cultures and long duration of antibacterial usage as well as the resistance situation.

Neonates and infants have historically been populations with some of the highest rates of candidemia [23-29]. In our study, BSI by *candida* species occurred more frequently among males, mainly in those over 65 years old. The reasons for the shift in burden from neonates to

Table 4 Factors associated with 30-day mortality by multivariate analysis

Variable	Odds ratio	95% Confidence interval	P-value
Complicated abdominal surgery	1.678	0.802-3.510	0.169
Presence of CVC	4.177	1.698-310.278	0.002
<i>C. tropicalis</i>	1.705	0.809-33.593	0.161
Treatment with fluconazole	0.523	0.247-31.110	0.091

CVC central venous catheter.

adults are likely multifactorial; some contribution may be due to changes in the prevalence of risk factors in the adult population. Increases in common risk factors such as ICU admission [30,31], or numbers of patients receiving immunosuppressive therapies [32] may have resulted in increase in the overall pool of patients at high risk for candidemia. The difference in the distribution of cases between genders could be related to the predominant presence of male patients in units where the use of invasive devices, broad-spectrum antibiotics, extensive surgical procedures, or advanced life support is frequently used.

Over the past 20 years, a shift towards non-*albicans* *Candida* species has been reported previously from the USA, Europe and Australia, although the precise pattern of causative species varies across countries [5]. The findings from our surveillance are partially supportive of these reports. We observed a significant predominance of non-*albicans* *Candida* species (76.7%), with *C. tropicalis* being the most common isolate (28.6%), followed by *C. albicans* (23.3%), *C. parapsilosis* (19.5%) and *C. glabrata* (8.3%). Traditionally, *C. tropicalis* has been the second most common *Candida* species recovered from blood [33]. Similarly, as previously reported at a hospital in China, *C. albicans* (57.8%) continued to play a dominant role in candidemia, followed by *C. tropicalis* (12.8%) [34]. In our report, *C. tropicalis* surpassed the other *Candida* species to become the most common species, we recognize that this finding may simply be a result of the small sample size, and the further studies with larger sample size are needed to verify it. It is worth mentioning that eight *C. pelliculosa*, seven *C. famata* and two *C. haemulonii* isolates were recovered during the study period, suggesting the diversity of the etiologic agents. ARTEMIS DISK Global antifungal surveillance also found an increase of the involvement of less-common *Candida* species during the 10.5-year study period and showed that species identification is important to diagnosis and surveillance [35].

As already reported [36], non-*albicans* *Candida* species were predominant in patients with haematological malignancies (83.3%), a finding in accordance with the global results of the ECMM survey [7]; moreover, *C. tropicalis* was frequently isolated in this group of patients, the prevalence of *C. tropicalis* among patients with haematological malignancies is consistent with previous reports [19].

The antifungal susceptibility patterns revealed that voriconazole has excellent in vitro activity overall against *Candida* species. Successful salvage therapy with voriconazole for the treatment of candidemia in patients intolerant or refractory to other antifungal agents has been reported [37]. Some studies showed that voriconazole may be a suitable agent for salvage therapy of invasive candidiasis, even in the setting of previous azole expo-

sure and *C. krusei* infection [36,38]. Most publications on antifungal resistance over the past 10 years have been concerned with resistance to triazole antifungals, especially fluconazole, itraconazole, and ketoconazole. For ketoconazole, it showed the existence of a sensitivity of 38.1% of strains studied, lower than the other three azoles. Ketoconazole resistance was observed in 50% of *C. albicans* and *C. parapsilosis*, respectively. Itraconazole resistance was observed for 30.5% of all *Candida* species and was also highest among *C. glabrata* (90.9% resistance), this sensitivity decline was similar to that previously published in Iowa Organisms Study [39]. In recent years, resistance to azole antifungal agents among *Candida* spp. is still uncommon. In Iceland, 97.3% of the *Candida* spp. isolates tested were susceptible to fluconazole [13]. A similar data has been reported from North India [40]. In contrast to other reports, antifungal resistance was a notable finding in our study and was mainly restricted to fluconazole. Our proportion of fluconazole-resistant isolates (53.9%) was higher than the rates observed with Spain (9.8%) [41]. We propose two potential reasons, first, the number of isolates in this study is still not high enough, therefore the rate of azole resistance is higher than clinical reports. Second, the increasing use of fluconazole as antifungal therapy leads to a reduction in susceptibility and the appearance of resistant strains. Some reports have demonstrated that candidemia due to non-*albicans* species increased and that was apparently correlated with an increasing use of azoles for prophylaxis or empirical treatment [42], in our study, almost all patients received empirical therapy, 65(45.9%) patients were treated with fluconazole, followed by voriconazole (18.8%), and caspofungin (11.3%). For the latter reason, it would be convenient to carry out antifungal susceptibility studies in order to establish the in vitro activities of antifungal agents against local isolates and also to detect shifts toward resistance as early as possible. When analyzed by species, apart from the intrinsically fluconazole-resistant species (*C. krusei*), the highest rate of resistance to fluconazole was for *C. glabrata* and *C. tropicalis* (more than 50%), which was consistent with other studies in whom the greatest resistance to fluconazole also showed *C. glabrata* (36%) [41]. Furthermore, discrepancies in vitro susceptibility to FLC rate of different strains studied in this single-center study could be associated to differences in species distribution of isolates tested in this study.

In the present study we decided to analyze prognostic factors in patients with candidemia, we found that complicated abdominal surgery, presence of CVC, neutropenia, candidemia due to *C. tropicalis*, poor treatment with fluconazole were predictors of mortality in the univariate analysis. Of all the variables significantly associated with mortality in the univariate analysis, presence

of CVC was the only predictive factor of mortality in the multivariate analysis. This is in agreement with the findings of a hospital population-based surveillance study [43]. In a study of pediatric candidemia, Candidemia-associated mortality has been found to be 31-72% [44]. Similarly, the crude 30-day mortality rate in our study was 26% for all patients with candidemia, which is in concordance with rates reported from Chinese tertiary-care centers, ranging from 26.4% to 33.3% [21,34]. A possible explanation for the relatively low mortality of nosocomial candidemia is the increase in empirical and/or pre-emptive use of fluconazole for presumed invasive candidiasis. Furthermore, although the hospital is a tertiary care hospital it rarely has patients with solid organ or bone marrow transplants. Thus, on average the patients in our hospital are less sick than in other hospitals. In our study, *C. tropicalis* was the species associated with the highest mortality rate (50%), besides being raised among the elderly, mortality is particularly high among patients with cancer (66.7% for haematological malignancies) as reported previously [33,45,46]. Certainly the severity of the underlying medical conditions has greatly influenced the crude mortality rate in these patient populations.

Conclusions

This report shows that candidemia is a significant source of morbidity in Nanjing, with a substantial burden of disease, mortality, and likely high associated costs. We concede that there are several potential limitations to the present study. First, this is a single-center study. Our conclusions might be influenced by the local ecology, management practices, infections control policy, or our own susceptibility patterns. Second, our analysis was restricted to adult patients. Therefore, our conclusions cannot be extrapolated to pediatric populations. Finally, the results of the multivariate analyses might be influenced by the sample size and the number of variables included in the models. However, it would be of immense value to establish surveillance of candidemia to develop and evaluate prevention strategies and to monitor for changes in incidence and resistance.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

FQL conceived, coordinated and designed the research; CFM performed the experiment, contributed to the acquisition, analysis and interpretation of data and drafted the manuscript. LNS, YAH, YW and MH participated in *Candida* spp. identification; QKQ participated in sample collection and data acquisition. All the authors have read and approved the final manuscript.

Acknowledgements

This work was supported financially by Jiangsu Science Foundation (BE2009673).

Received: 6 January 2013 Accepted: 18 July 2013
Published: 22 July 2013

Reference

1. Tortorano AM, Dho G, Prigitano A, Breda G, Grancini A, Emmi V, Cavanna C, Marino G, Morero S, Ossi C: **Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006–2008).** *Mycoses* 2012, **55**(1):73–79.
2. Kourkoumpetis T, Manolaki D, Velmahos G, Chang Y, Alam HB, De Moya MM, Sailhamer EA, Mylonakis E: **Candida infection and colonization among non-trauma emergency surgery patients.** *Virulence* 2010, **1**(5):359.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: **Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.** *Clin Infect Dis* 2004, **39**(3):309–317.
4. Marchetti O, Bille J, Fluckiger U, Eggmann P, Ruef C, Garbino J, Calandra T, Glauser MP, Täuber MG, Pittet D: **Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000.** *Clin Infect Dis* 2004, **38**(3):311–320.
5. Poikonen E, Lyytikäinen O, Anttila VJ, Koivula I, Lumio J, Kotilainen P, Syrjälä H, Ruutu P: **Secular trend in candidemia and the use of fluconazole in Finland, 2004–2007.** *BMC Infect Dis* 2010, **10**(1):312.
6. Zaragoza R, Pemán J: **The diagnostic and therapeutic approach to fungal infections in critical care settings.** *Adv Sepsis* 2008, **6**:90–98.
7. Tortorano A, Peman J, Bernhardt H, Klingspor L, Kibbler C, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S: **Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study.** *Eur J Clin Microbiol Infect Dis* 2004, **23**(4):317–322.
8. De Rosa FG, Trecarichi EM, Montruccchio C, Losito AR, Raviolo S, Posteraro B, Corcione S, Di Giambenedetto S, Fossati L, Sanguinetti M: **Mortality in patients with early- or late-onset candidaemia.** *J Antimicrob Chemother* 2013, **68**(4):927–935.
9. Olaechea P, Palomar M, León-Gil C, Alvarez-Lerma F, Jorda R, Nolla-Salas J, León-Regidor M: **Economic impact of Candida colonization and Candida infection in the critically ill patient.** *Eur J Clin Microbiol Infect Dis* 2004, **23**(4):323–330.
10. Oberoi JK, Watal C, Goel N, Raveendran R, Datta S, Prasad K: **Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India.** *Indian J Med Res* 2012, **136**(6):997.
11. Magill SS, Shields C, Sears CL, Choti M, Merz WG: **Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.** *J Clin Microbiol* 2006, **44**(2):529–535.
12. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B: **Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006).** *Crit Care Med* 2009, **37**(5):1612–1618.
13. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M: **Nationwide Study of Candidemia, Antifungal Use, and Antifungal Drug Resistance in Iceland, 2000 to 2011.** *J Clin Microbiol* 2013, **51**(3):841–848.
14. Li FQ, Ma CF, Shi LN, Lu JF, Wang Y, Huang M, Kong QQ: **Diagnostic value of immunoglobulin G antibodies against Candida enolase and fructose-bisphosphate aldolase for candidemia.** *BMC Infect Dis* 2013, **13**:253.
15. Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M: **Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003.** *J Clin Microbiol* 2005, **43**(4):1829–1835.
16. Colosi I, Faure O, Lebeau B, Colosi H, Junie M, Pelloux H: **Comparison of two methods, E-test® and Neo-Sensitabs® tablet diffusion assay, for testing susceptibility of 93 Candida strains to amphotericin B, fluconazole, voriconazole, and caspofungin.** *Rev Sci Parasitol* 2009, **10**(1/2):112–122.
17. Diekema DJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Jones RN, Pfaffer MA: **A global evaluation of voriconazole activity tested against recent clinical isolates of <i>Candida</i> spp.** *Diagn Microbiol Infect Dis* 2009, **63**(2):233–236.
18. Marcos-Arias C, Eraso E, Madariaga L, Carrillo-Muñoz AJ, Quindós G: **In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis.** *Mycopathologia* 2012, **173**(1):35–46.
19. Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, Kjældgaard P, Knudsen JD, Kristensen L, Møller J, Nielsen L: **National surveillance of fungemia in Denmark (2004 to 2009).** *J Clin Microbiol* 2011, **49**(1):325–334.
20. Rennert G, Rennert H, Pitlik S, Finkelstein R, Kitzes-Cohen R: **Epidemiology of candidemia—a nationwide survey in Israel.** *Infection* 2000, **28**(1):26–29.
21. Li D, Zhang W, Zheng S, Ma Z, Zhang P, Liu Z: **Surveillance study of candidemia in cancer patients in North China.** *Med Mycol* 2013, **51**(4):378–384.
22. Motta AL, Almeida GMD, Almeida Júnior JN, Burattini MN, Rossi F: **Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex.** *Braz J Infect Dis* 2010, **14**(5):441–448.
23. Roldes E: **Invasive candidiasis in neonates and children.** *Early Hum Dev* 2011, **87**:S75–S76.
24. Fridkin SK: **Candidemia is costly—plain and simple.** *Clin Infect Dis* 2005, **41**(9):1240–1241.
25. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA: **Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.** *J Clin Microbiol* 2004, **42**(4):1519–1527.
26. Pfaffer M, Diekema D: **Epidemiology of invasive candidiasis: a persistent public health problem.** *Clin Microbiol Rev* 2007, **20**(1):133–163.
27. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T: **Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995–2004.** *Pediatrics* 2006, **117**(5):1680–1687.
28. Chang A, Neofytos D, Horn D: **Candidemia in the 21st century.** *Future Microbiol* 2008, **3**(4):463–472.
29. Shetty SS, Harrison LH, Hajjeh RA, Taylor T, Mirza SA, Schmidt AB, Sanza LT, Shutt KA, Fridkin SK: **Determining risk factors for candidemia among newborn infants from population-based surveillance: Baltimore, Maryland, 1998–2000.** *Pediatr Infect Dis J* 2005, **24**(7):601–604.
30. Lerolle N, Trinquart L, Bornstain C, Tadié JM, Imbert A, Diehl JL, Fagon JY, Guérot E: **Increased intensity of treatment and decreased mortality in elderly patients in an intensive care unit over a decade.** *Crit Care Med* 2010, **38**(1):59.
31. Halpern NA, Pastores SM: **Critical care medicine in the United States 2000–2005: An analysis of bed numbers, occupancy rates, payer mix, and costs.** *Crit Care Med* 2010, **38**(1):65.
32. Giri S, Kindo AJ: **A review of Candida species causing blood stream infection.** *Indian J Med Microbiol* 2012, **30**(3):270–278.
33. Ann Chai LY, Denning DW, Warn P: **Candida tropicalis in human disease.** *Crit Rev Microbiol* 2010, **36**(4):282–298.
34. Wu J-Q, Zhu L-P, Ou X-T, Xu B, Hu X-P, Wang X, Weng X-H: **Epidemiology and risk factors for non-Candida albicans candidemia in non-neutropenic patients at a Chinese teaching hospital.** *Medical Mycology* 2011, **49**(5):552–555.
35. Pfaffer M, Diekema D, Gibbs D, Newell V, Bijie H, Dzierzanowska D, Klimko N, Letscher-Bru V, Lisalova M, Muehlethaler K: **Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.** *J Clin Microbiol* 2009, **47**(1):117–123.
36. Peman J, Canton E, Gobernado M: **Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain.** *Eur J Clin Microbiol Infect Dis* 2005, **24**(1):23–30.
37. Ostrosky-Zeichner L, Lashof AO, Kullberg B, Rex J: **Voriconazole salvage treatment of invasive candidiasis.** *Eur J Clin Microbiol Infect Dis* 2003, **22**(11):651–655.
38. Muñoz P, Sánchez-Somolinos M, Alcalá L, Rodríguez-Crèixems M, Peláez T, Bouza E: **Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.** *J Antimicrob Chemother* 2005, **55**(2):188–193.
39. Diekema D, Messer S, Brueggemann A, Coffman S, Doern G, Herwaldt L, Pfaffer M: **Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.** *J Clin Microbiol* 2002, **40**(4):1298–1302.
40. Xess I, Jain N, Hasan F, Mandal P, Banerjee U: **Epidemiology of candidemia in a tertiary care centre of north India: 5-year study.** *Infection* 2007, **35**(4):256–259.

41. Quindós G, Abarca L, Carrillo-Muñoz AJ, Arévalo MP, Bornay FJ, Casals JB, Molina JMH, Iglesias I, Linares M, Martín-Mazuelos E: **Multicenter survey of in vitro antifungal resistance in yeasts of medical importance isolated from Spanish patients.** *Rev Iberoam Micol* 1999, **16**:97–100.
42. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C: **Epidemiological trends in nosocomial candidemia in intensive care.** *BMC Infect Dis* 2006, **6**(1):21.
43. Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B, Soro O, Cauda R, Viscoli C, Tumbarello M: **Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals.** *Diagn Microbiol Infect Dis* 2007, **58**(3):325–331.
44. Al-Tawfiq JA: **Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital.** *Int J Infect Dis* 2007, **11**:239–244.
45. Costa S, Marinho I, Araujo E, Manrique A, Levin E: **Nosocomial fungaemia: a 2-year prospective study.** *J Hosp Infect* 2000, **45**(1):69–72.
46. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT: **Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study.** *Clin Infect Dis* 2001, **33**(2):177–186.

doi:10.1186/1471-2334-13-337

Cite this article as: Ma et al.: Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China. *BMC Infectious Diseases* 2013 **13**:337.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

